Zhong, Wenge et al. published their patent in 2020 |CAS: 386704-04-7

The Article related to benzimidazole derivative preparation glp1r agonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Quality Control of (6-(Trifluoromethyl)pyridin-3-yl)methanol

On October 15, 2020, Zhong, Wenge; Guo, Wei published a patent.Quality Control of (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Benzimidazole derivatives as Glp-1R agonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

Provided herein are benzimidazole compounds of formula I and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alc. fatty liver disease, non-alc. steatohepatitis, and cardiovascular disease. Compounds of formula I wherein dashed double bond is either as single bond or a double bond; EE is COOH, -COCF3, -CH(OH)CF3, -CO-NH-CN, -CO-NH-OH, etc.; X1-X5 are independently N, CH; W is O, S, (un)substituted CH, NH and derivatives; ring B is 6-membered heteroaryl, 6-membered monocyclic ring, Ph; Y1 and Y3-Y4 are independently N, CH; T6-T8 are independently N, (un)substituted VH; ring C is cyclohexyl, Ph, pyridinyl; L is (un)substituted CH2, S, O, NH and derivatives; ring D is bicyclic heteroaryl; EE is COOH, -COCF3, -CH(OH)CF3, -CONH-CN, -CONH-OH, -CO-NH-OMe, etc.; Rb is H, C1-6 alkyl, C1-6 alkoxy, etc.; R1 is H, halo, CN, OH, C1-6 alkyl, C1-6 alkoxy, etc.; R2 is H, D, halo, CN, OH, oxo, C1-6 alkyl, etc.; R3 is H, D, CN, OH, oxo, C1-6 alkyl, C1-6 alkoxy, etc.; and their pharmaceutically acceptable salts, stereoisomers, solvates, hydrates as Glp-1R agonists in the treatment of diseases thereof, are claimed. Example compound II was prepared starting from 4-bromo-3-fluorobenzeneacetonitrile by using alcoholysis, heterocyclization, cross-coupling, and hydrolysis as the key steps. All the invention compounds were evaluated for their Glp-1R agonistic activity. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Quality Control of (6-(Trifluoromethyl)pyridin-3-yl)methanol

The Article related to benzimidazole derivative preparation glp1r agonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Quality Control of (6-(Trifluoromethyl)pyridin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts